Aliénor Berges

1.2k total citations
34 papers, 843 citations indexed

About

Aliénor Berges is a scholar working on Molecular Biology, Oncology and Statistics and Probability. According to data from OpenAlex, Aliénor Berges has authored 34 papers receiving a total of 843 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 12 papers in Oncology and 5 papers in Statistics and Probability. Recurrent topics in Aliénor Berges's work include PARP inhibition in cancer therapy (9 papers), DNA Repair Mechanisms (7 papers) and Statistical Methods in Clinical Trials (5 papers). Aliénor Berges is often cited by papers focused on PARP inhibition in cancer therapy (9 papers), DNA Repair Mechanisms (7 papers) and Statistical Methods in Clinical Trials (5 papers). Aliénor Berges collaborates with scholars based in United Kingdom, United States and France. Aliénor Berges's co-authors include Louise Cookson, Duncan Richards, Massimo Pinzani, James Moon, Thirusha Lane, Philip N. Hawkins, Mark B. Pepys, Julian D. Gillmore, Marianna Fontana and James M. Ritter and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Aliénor Berges

32 papers receiving 825 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Aliénor Berges United Kingdom	14	538	311	151	79	74	34	843
Claus G. Haase Germany	14	566 1.1×	328 1.1×	192 1.3×	60 0.8×	59 0.8×	28	1.4k
Min Jueng Kang South Korea	20	642 1.2×	137 0.4×	203 1.3×	81 1.0×	28 0.4×	36	1000
Xiaoming Shen China	20	533 1.0×	477 1.5×	143 0.9×	77 1.0×	32 0.4×	34	1.2k
Lee Anne McLean United States	9	422 0.8×	176 0.6×	74 0.5×	32 0.4×	86 1.2×	12	740
Axel Ullrich Germany	4	960 1.8×	305 1.0×	119 0.8×	133 1.7×	67 0.9×	5	1.4k
Ivan Presta Italy	19	318 0.6×	125 0.4×	150 1.0×	111 1.4×	66 0.9×	43	913
Rainer Girgert Germany	20	366 0.7×	199 0.6×	45 0.3×	59 0.7×	83 1.1×	38	988
Xueqiu Jian United States	11	940 1.7×	75 0.2×	50 0.3×	71 0.9×	60 0.8×	17	1.5k
Moulay Driss Rochdi Canada	14	552 1.0×	70 0.2×	70 0.5×	56 0.7×	59 0.8×	15	817
Hee‐Dong Han United States	11	424 0.8×	192 0.6×	176 1.2×	131 1.7×	18 0.2×	11	845

Countries citing papers authored by Aliénor Berges

Since Specialization

Citations

This map shows the geographic impact of Aliénor Berges's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aliénor Berges with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aliénor Berges more than expected).

Fields of papers citing papers by Aliénor Berges

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aliénor Berges. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aliénor Berges. The network helps show where Aliénor Berges may publish in the future.

Co-authorship network of co-authors of Aliénor Berges

This figure shows the co-authorship network connecting the top 25 collaborators of Aliénor Berges. A scholar is included among the top collaborators of Aliénor Berges based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aliénor Berges. Aliénor Berges is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schalkwijk, Stein, et al.. (2026). Straight to Phase III : Model‐Informed Approach Speeds Depemokimab Clinical Development in Interleukin‐5‐Driven Diseases. Clinical Pharmacology & Therapeutics. 119(4). 1005–1015.

Zecchin, Chiara, et al.. (2024). Predicting the Long‐Term Effects of Therapeutic Neutralization of Oncostatin M on Human Hematopoiesis. Clinical Pharmacology & Therapeutics. 116(3). 703–715. 4 indexed citations

Kim, Seung Tae, Simon A. Smith, Peter G. Mortimer, et al.. (2021). Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer. Clinical Cancer Research. 27(17). 4700–4709. 61 indexed citations

Yap, Timothy A., Matthew Krebs, Sophie Postel‐Vinay, et al.. (2021). Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study. Clinical Cancer Research. 27(19). 5213–5224. 71 indexed citations

Berges, Aliénor, et al.. (2021). QT Prolongation Risk Assessment in Oncology: Lessons Learned From Small‐Molecule New Drug Applications Approved During 2011‐2019. The Journal of Clinical Pharmacology. 61(8). 1106–1117. 12 indexed citations

Sepp, Armin, et al.. (2019). Computer-assembled cross-species/cross-modalities two-pore physiologically based pharmacokinetic model for biologics in mice and rats. Journal of Pharmacokinetics and Pharmacodynamics. 46(4). 339–359. 22 indexed citations

Berges, Aliénor, et al.. (2019). Item Response Model Adaptation for Analyzing Data from Different Versions of Parkinson’s Disease Rating Scales. Pharmaceutical Research. 36(9). 135–135. 13 indexed citations

Zhou, Diansong, Jianguo Li, Khanh Bui, et al.. (2018). Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology Patients. Clinical Pharmacokinetics. 58(5). 615–625. 25 indexed citations

Richards, Duncan, Louise Cookson, Aliénor Berges, et al.. (2015). Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. New England Journal of Medicine. 373(12). 1106–1114. 261 indexed citations

10.

Berges, Aliénor, Jonathan Bullman, Stewart Bates, et al.. (2015). Ozanezumab Dose Selection for Amyotrophic Lateral Sclerosis by Pharmacokinetic-Pharmacodynamic Modelling of Immunohistochemistry Data from Patient Muscle Biopsies. PLoS ONE. 10(2). e0117355–e0117355. 6 indexed citations

11.

Sepp, Armin, Aliénor Berges, Andrew Sanderson, & Guy Meno‐Tetang. (2015). Development of a physiologically based pharmacokinetic model for a domain antibody in mice using the two-pore theory. Journal of Pharmacokinetics and Pharmacodynamics. 42(2). 97–109. 27 indexed citations

12.

Berges, Aliénor, et al.. (2015). Comparing probabilistic and descriptive analyses of time–dose–toxicity relationship for determining no-observed-adverse-effect level in drug development. Toxicology and Applied Pharmacology. 288(2). 240–248. 3 indexed citations

13.

Grove, Richard, Conn Harrington, I.J.M. Beresford, et al.. (2014). A Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of the H<sub>3</sub> Receptor Antagonist, GSK239512 as a Monotherapy in Subjects with Mild-to-Moderate Alzheimer’s Disease. Current Alzheimer Research. 11(1). 47–58. 87 indexed citations

14.

Nathan, Pradeep J., Nicola Scott, Aliénor Berges, et al.. (2013). The Safety, Tolerability, Pharmacokinetics and Cognitive Effects of GSK239512, a Selective Histamine H<sub>3</sub> Receptor Antagonist in Patients with Mild to Moderate Alzheimer’s Disease: A Preliminary Investigation. Current Alzheimer Research. 10(3). 240–251. 54 indexed citations

15.

Berges, Aliénor, Vincent J. Cunningham, Roger N. Gunn, & Stefano Zamuner. (2013). Non linear mixed effects analysis in PET PK-receptor occupancy studies. NeuroImage. 76. 155–166. 5 indexed citations

16.

Harden, R. Norman, Roy Freeman, Michelle Rainka, et al.. (2013). A Phase 2a, Randomized, Crossover Trial of Gabapentin Enacarbil for the Treatment of Postherpetic Neuralgia in Gabapentin Inadequate Responders. Pain Medicine. 14(12). 1918–1932. 7 indexed citations

17.

Berges, Aliénor & Chao Chen. (2013). Dose finding by concentration-response versus dose-response: a simulation-based comparison. European Journal of Clinical Pharmacology. 69(7). 1391–1399. 4 indexed citations

18.

Berges, Aliénor, et al.. (2012). Pharmacokinetics, Safety, and Tolerability Following the Administration of a Single Dose of a Combination Tablet Containing Sumatriptan and Naproxen Sodium in Adolescent Patients With Migraine and in Healthy Adult Volunteers. Clinical Pharmacology in Drug Development. 1(3). 85–92. 2 indexed citations

19.

Berges, Aliénor, et al.. (2010). Pharmacokinetics and tolerability of sumatriptan after single-dose administration of a fixed-dose combination tablet of sumatriptan/naproxen sodium 85/500 mg followed two hours later by subcutaneous sumatriptan 4- or 6-mg injection: A randomized, open-label, three-period crossover study in healthy volunteers. Clinical Therapeutics. 32(6). 1165–1177. 6 indexed citations

20.

Berges, Aliénor, Silvy Laporte, Magali Epinat, et al.. (2007). Anti‐factor Xa activity of enoxaparin administered at prophylactic dosage to patients over 75 years old. British Journal of Clinical Pharmacology. 64(4). 428–438. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact